In vitro evaluation of dichloro-bis(pyrazole)palladium(II) and dichloro-bis(pyrazole)platinum(II) complexes as anticancer agents

IntroductionCisplatin (cis-diamminedichloroplatinum) was first identified for its anti-bacterial activity, and was later also shown to be an efficient anticancer agent. However, the therapeutic use of this anticancer drug is somewhat limited by its toxic side effects, which include nephrotoxicity, nausea, and vomiting. Furthermore the development of drug-resistant tumours is commonly observed following therapy with cisplatin. Hence there is a need for improved platinum derived drugs to overcome these limitations.AimsApoptosis contributes significantly to the cytotoxic effects of anticancer agents such as cisplatin; therefore in this study the potential anticancer properties of a series of pyrazole palladium(II) and platinum(II) complexes, [(3,5-R2pz)2PdCl2] {R = H (1), R = Me (2)} and [(3,5-R2pz)2PtCl2] {R = H (3), R = Me (4)}, were evaluated by assessment of their pro-apoptotic activity.MethodsThe induction of apoptosis was measured in CHO cells by the detection of phosphatidylserine (PS) exposure using the annexin V and APOPercentage™ assays; DNA fragmentation using the Terminal deoxynucleotide transferase dUTP Nick End Labelling (TUNEL) assay; and the detection of activated caspase-3.ResultsThe platinum complexes were shown to be considerably more active than the palladium complexes, with complex 3 demonstrating the highest level of cytotoxic and pro-apoptotic activity. The LD50 values for complex 3 and cisplatin were 20 and 70 μM, respectively, demonstrating that the cytotoxic activity for complex 3 was three times higher than for cisplatin. Various human cancer cell lines, including CaSki, HeLa, as well as the p53 mutant Jurkat T cell line were also shown to be susceptible to complex 3.ConclusionsCollectively, this in vitro study provides insights into action of palladium and platinum complexes and demonstrates the potential use of these compounds, and in particular complex 3, in the development of new anticancer agents.

[1]  H. Frankish.  15 million new cancer cases per year by 2020, says WHO , 2003, The Lancet.

[2]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[3]  G. Inman,et al.  DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. , 1995, The EMBO journal.

[4]  J. Turchi,et al.  Cisplatin-induced Apoptosis Proceeds by Caspase-3-dependent and -independent Pathways in Cisplatin-resistant and -sensitive Human Ovarian Cancer Cell Lines Proteolytic Degradation of Procaspase-3 Was Observed in Both the Cp70 and C30 Cells following Ic 50 Cisplatin Treatment, Whereas No Pro- Teolyze , 2022 .

[5]  L. Marzilli,et al.  Platinum complexes with NH groups on the carrier ligand and with only one guanine or hypoxanthine derivative. Informative models for assessing relative nucleobase and nucleotide hydrogen-bond interactions with amine ligands in solution. , 2004, Inorganic chemistry.

[6]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[7]  Y. Pommier,et al.  Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells. , 2004, Biochemical pharmacology.

[8]  M. Shin,et al.  Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. , 2002, Blood.

[9]  R. Brown,et al.  Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. , 1996, Cancer research.

[10]  S. Lippard,et al.  Cisplatin and DNA repair in cancer chemotherapy. , 1995, Trends in biochemical sciences.

[11]  L. Kèlland,et al.  In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. , 1998, British Journal of Cancer.

[12]  J. Craig,et al.  Flow cytometry using annexin V can detect early apoptosis in peripheral blood stem cell harvests from patients with leukaemia and lymphoma , 1998, Bone Marrow Transplantation.

[13]  J. Turchi,et al.  Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines. , 1997, Cancer research.

[14]  H. Tesch,et al.  Point mutations in the conserved regions of the p53 tumour suppressor gene do not account for the transforming process in the Jurkat acute lymphoblastic leukemia T-cells. , 1992, Leukemia.

[15]  H. Yamamoto,et al.  Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. , 1999, Cancer research.

[16]  I. Guzei,et al.  Synthesis and evaluation of substituted pyrazoles palladium(II) complexes as ethylene polymerization catalysts , 2002 .

[17]  S. Lippard,et al.  Repair of cisplatin--DNA adducts by the mammalian excision nuclease. , 1996, Biochemistry.

[18]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[19]  C. Mock,et al.  Cisplatin analogues with 2,2?-dipyridylamine ligands and their reactions with DNA model nucleobases , 2003 .

[20]  J. Trosko,et al.  Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.

[21]  T. Lindahl,et al.  DNA excision repair pathways. , 1997, Current opinion in genetics & development.

[22]  A. Rossof,et al.  Preliminary clinical experience with cis‐diamminedichloroplatinum (II) (NSC 119875, CACP) , 1972, Cancer.

[23]  W. Park,et al.  Inactivating mutations of CASPASE-7 gene in human cancers , 2003, Oncogene.

[24]  C. Potten,et al.  Education and debate , 2022 .

[25]  J. Reedijk,et al.  Intrastrand bis(guanine) chelation of trinucleoside diphosphate d(CpGpG) to cis-platinum: an x-ray single-crystal structure analysis , 1987 .

[26]  J. Zlatanova,et al.  Proteins that specifically recognize cisplatin‐damaged DNA: a clue to anticancer activity of cisplatin , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  R. Kociba,et al.  Inhibition of Dunning asc itic leukemia and Walker 256 carcinosarcoma with cis-diamminedichloroplatinum (NSC-119875). , 1970, Cancer chemotherapy reports.

[28]  G. Chu,et al.  Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. , 1994, The Journal of biological chemistry.

[29]  N. Saijo,et al.  Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells. , 1999, Oncology reports.

[30]  T. Jacks,et al.  p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  W. Earnshaw,et al.  Induction of apoptosis by cancer chemotherapy. , 2000, Experimental cell research.

[32]  J. Reedijk,et al.  Synthesis, Crystal Structure, Antitumor Activity, and DNA-Binding Properties of the New Active Platinum Compound (Bis(N-methylimidazol-2-yl)carbinol)dichloroplatinum(II), Lacking a NH Moiety, and of the Inactive Analog Dichloro(N1,N1‘-dimethyl-2,2‘-biimidazole)platinum(II) , 1996 .

[33]  K. Kawakami,et al.  Syntheses, antitumor activity, and molecular mechanics studies of cis-PtCl2(pzH)2 (pzH=pyrazole) and related complexes. Crystal structure of a novel Magnus-type double-salt [Pt(pzH)4][PtCl4][cis-PtCl2(pzH)2]2 involving two perpendicularly aligned 1D chains , 2000 .

[34]  S. Lippard,et al.  HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  坂平 英樹.  Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis , 2000 .

[36]  I. Roninson,et al.  Identification of p53 genetic suppressor elements which confer resistance to cisplatin , 1997, Oncogene.

[37]  Ellen Borenfreund,et al.  In vitro cytotoxicity assays. Potential alternatives to the Draize ocular allergy test , 1984, Cell Biology and Toxicology.

[38]  S. Lowe,et al.  Apoptosis in cancer. , 2000, Carcinogenesis.

[39]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[40]  J. Misset,et al.  Chemotherapy for ovarian cancer. , 1996, The New England journal of medicine.

[41]  P. Jordan,et al.  Molecular mechanisms involved in cisplatin cytotoxicity , 2000, Cellular and Molecular Life Sciences CMLS.

[42]  F. Albert Cotton,et al.  Advanced Inorganic Chemistry , 1999 .

[43]  Einhorn,et al.  Testicular cancer: an oncological success story. , 1997, Clinical Cancer Research.

[44]  A. Ozkul,et al.  Synthesis, cytotoxic activity on MCF-7 cell line and mutagenic activity of platinum(II) complexes with 2-substituted benzimidazole ligands. , 2003, European journal of medicinal chemistry.

[45]  W. Park,et al.  Inactivating mutations of caspase-8 gene in colorectal carcinomas. , 2003, Gastroenterology.